HK1131141A1 - Imidazolothiazole compounds for the treatment of disease - Google Patents

Imidazolothiazole compounds for the treatment of disease

Info

Publication number
HK1131141A1
HK1131141A1 HK09110846A HK09110846A HK1131141A1 HK 1131141 A1 HK1131141 A1 HK 1131141A1 HK 09110846 A HK09110846 A HK 09110846A HK 09110846 A HK09110846 A HK 09110846A HK 1131141 A1 HK1131141 A1 HK 1131141A1
Authority
HK
Hong Kong
Prior art keywords
disease
treatment
imidazolothiazole compounds
imidazolothiazole
compounds
Prior art date
Application number
HK09110846A
Other languages
English (en)
Inventor
Shripad Bhagwat
Qi Chao
Robert M Grotzfeld
Hitesh K Patel
Kelly G Sprankle
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of HK1131141A1 publication Critical patent/HK1131141A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK09110846A 2006-03-17 2009-11-19 Imidazolothiazole compounds for the treatment of disease HK1131141A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74354306P 2006-03-17 2006-03-17
PCT/US2007/006613 WO2007109120A2 (en) 2006-03-17 2007-03-16 Imidazolothiazole compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
HK1131141A1 true HK1131141A1 (en) 2010-01-15

Family

ID=38522967

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09110846A HK1131141A1 (en) 2006-03-17 2009-11-19 Imidazolothiazole compounds for the treatment of disease

Country Status (23)

Country Link
US (6) US7820657B2 (ja)
EP (1) EP2001892B1 (ja)
JP (2) JP4610668B2 (ja)
KR (2) KR101549364B1 (ja)
CN (1) CN101448843B (ja)
AU (1) AU2007227495B2 (ja)
BR (1) BRPI0708823B1 (ja)
CA (1) CA2646437C (ja)
DK (1) DK2001892T3 (ja)
ES (1) ES2422890T3 (ja)
HK (1) HK1131141A1 (ja)
IL (1) IL194076A (ja)
MX (1) MX2008011684A (ja)
MY (1) MY145070A (ja)
NO (1) NO342985B1 (ja)
NZ (1) NZ571566A (ja)
PL (1) PL2001892T3 (ja)
PT (1) PT2001892E (ja)
RU (1) RU2441011C2 (ja)
SI (1) SI2001892T1 (ja)
TW (1) TWI409267B (ja)
WO (1) WO2007109120A2 (ja)
ZA (1) ZA200808178B (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2001892E (pt) 2006-03-17 2013-07-04 Ambit Biosciences Corp Compostos de imidazolotiazole para o tratamento de doenças proliferativas
WO2009038757A2 (en) * 2007-09-19 2009-03-26 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
EP2205244B1 (en) * 2007-11-08 2013-08-21 Ambit Biosciences Corporation Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy-)imidazo-[2,1-b]-[1,3]-benzothiazol-2-yl]-phenyl}urea to treat proliferative disease
US7825214B2 (en) * 2008-01-15 2010-11-02 Johns Manville Purified styrene-maleic anhydride polymer binder
WO2010054058A1 (en) * 2008-11-06 2010-05-14 Ambit Bioscience Corporation Imidazolothiazole compounds as modulators of protein kinase
EP2218464A1 (en) * 2009-02-11 2010-08-18 Technische Universität München Compounds for non-invasive measurement of aggregates of amyloid peptides
EP2410987B1 (en) * 2009-03-23 2018-05-16 Ambit Biosciences Corporation Methods of treatment using combination therapy
PL2429524T3 (pl) * 2009-05-14 2020-08-24 Ambit Biosciences Corporation Suszony rozpyłowo preparat AC220
EP2305688A1 (en) 2009-09-28 2011-04-06 Université de la Méditerranée - Aix-Marseille II Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors
CN104447801A (zh) * 2009-11-05 2015-03-25 埃姆比特生物科学公司 用于制备咪唑并[2,1-b][1,3]苯并噻唑衍生物的方法
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
CR20170098A (es) 2010-05-20 2017-07-17 Array Biopharma Inc Compuestos macrociclicos como inhibidores de quinasa trk
DE102011113749A1 (de) * 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
ES2586527T3 (es) * 2011-10-14 2016-10-17 Ambit Biosciences Corporation Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
AU2013250378B2 (en) 2012-04-17 2016-01-14 Fujifilm Corporation Nitrogen-containing heterocyclic compound or salt thereof
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513259B (zh) * 2013-09-26 2017-06-16 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
CN104513258B (zh) * 2013-09-26 2018-04-03 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
KR101744033B1 (ko) 2013-10-16 2017-06-07 후지필름 가부시키가이샤 함질소 복소환 화합물의 염 또는 그 결정, 의약 조성물 및 flt3 저해제
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN106659765B (zh) 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
CA2952083C (en) 2014-07-17 2023-01-24 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
JP6257782B2 (ja) 2014-08-22 2018-01-10 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
JP6538153B2 (ja) * 2014-09-10 2019-07-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）阻害剤としての新規な化合物
CN105461709B (zh) * 2014-09-26 2020-01-21 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
CN105801602B (zh) * 2014-12-31 2018-05-04 四川大学 5-叔丁基异噁唑-3-基-3-(4-取代苯基)脲衍生物及其制备方法和用途
ES2968789T3 (es) 2015-02-20 2024-05-14 Daiichi Sankyo Co Ltd Procedimiento combinado para el tratamiento del cáncer
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
BR112018068532A2 (pt) 2016-03-15 2019-01-29 Oryzon Genomics Sa combinações de inibidores de lsd1 para o tratamento de malignidades hematológicas
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
IT201900015030A1 (it) 2019-08-26 2021-02-26 Univ Degli Studi Di Palermo Nuovi agenti terapeutici per il trattamento di patologie ematologiche
WO2021180008A1 (zh) * 2020-03-11 2021-09-16 暨南大学 含脲结构的三芳环化合物及其应用
CN111362972B (zh) * 2020-04-28 2021-08-24 江南大学 一种苯并咪唑并[2,1-b]噻唑类化合物及其应用
IL279972A (en) * 2021-01-05 2022-08-01 Anima Biotech Inc Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment
WO2024010762A1 (en) * 2022-07-03 2024-01-11 Anima Biotech Inc. C-myc mrna translation modulators and uses thereof in the treatment of cancer
CN115650978A (zh) * 2022-10-16 2023-01-31 河南师范大学 一种7-烷氧基二氢咪唑并[4,5-b]哌啶-2-硫酮类化合物的合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129432C (ja) 1964-02-29
NL129626C (ja) 1964-04-08
US3210370A (en) 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4354970A (en) 1980-03-07 1982-10-19 Eastman Kodak Company Indoline coupled isothiazole azo dyes
JPS56138196A (en) 1980-03-29 1981-10-28 Yamanouchi Pharmaceut Co Ltd Imidazo (2,1-b)benzothiazole derivative
JPS5740492A (en) 1980-08-22 1982-03-06 Yamanouchi Pharmaceut Co Ltd Novel 2-phenylimidazo 2,1-b benzothiazole derivative
JPS57149288A (en) 1981-03-12 1982-09-14 Yamanouchi Pharmaceut Co Ltd Imidazo(2,1-b)benzothiazole derivative
EP0082715A3 (en) * 1981-12-21 1984-01-11 Viragate Limited A target apparatus
JPS5978194A (ja) * 1982-10-27 1984-05-04 Yamanouchi Pharmaceut Co Ltd ２−フエニルイミダゾ〔２，１−ｂ〕ベンゾチアゾ−ルの新規誘導体およびその製造法
US4464384A (en) 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US4880824A (en) 1987-09-21 1989-11-14 Ortho Pharmaceutical Corporation Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0524055A1 (fr) 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
JPH05107705A (ja) 1991-10-17 1993-04-30 Konica Corp 新規な写真用カプラー
ES2126636T3 (es) 1992-05-19 1999-04-01 Adir Derivados del bencimidazol con actividad antidiabetica y antiagregante plaquetaria.
FR2699920B1 (fr) 1992-12-24 1995-02-10 Synthelabo Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
FR2700546B1 (fr) 1993-01-15 1995-02-17 Synthelabo Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
EP0607076A1 (fr) * 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
FR2722501B1 (fr) 1994-07-13 1996-08-09 Synthelabo Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
US5466799A (en) * 1994-08-08 1995-11-14 Iowa State University Research Foundation, Inc. Synthesis of benzodiazepines
CA2215197A1 (en) 1995-03-13 1996-09-19 Shigeyuki Tasaka Imidazothiazole compound
AU3783497A (en) 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
FR2759698B1 (fr) 1997-02-20 1999-03-19 Synthelabo Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
UA71904C2 (en) 1997-12-22 2005-01-17 Compounds and methods of treating by inhibiting raf kinase using heterocyclic substituted urea derivatives
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de) 1999-02-09 2000-08-10 Bayer Ag Oxazolidinone und ihre Verwendung als antibakterielle Mittel
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
JP2001048786A (ja) * 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001192386A (ja) 1999-10-29 2001-07-17 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
AU7887501A (en) 2000-07-06 2002-01-21 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030143199A1 (en) 2001-10-09 2003-07-31 Carson Dennis A. Use of STAT-6 inhibitors as therapeutic agents
US20040127719A1 (en) 2002-03-08 2004-07-01 Kexin Yang Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same
CA2506796A1 (en) 2002-11-25 2004-06-10 Pharmacia Corporation Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
CA2509561A1 (en) 2002-12-18 2004-07-15 Mallinckrodt Inc. Synthesis of heteroaryl acetamides
KR100647583B1 (ko) 2003-10-07 2006-11-17 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
JP2007512255A (ja) 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション キナーゼ調節因子としての尿素誘導体
PT2001892E (pt) * 2006-03-17 2013-07-04 Ambit Biosciences Corp Compostos de imidazolotiazole para o tratamento de doenças proliferativas
WO2009038757A2 (en) * 2007-09-19 2009-03-26 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
EP2205244B1 (en) 2007-11-08 2013-08-21 Ambit Biosciences Corporation Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy-)imidazo-[2,1-b]-[1,3]-benzothiazol-2-yl]-phenyl}urea to treat proliferative disease
WO2010054058A1 (en) * 2008-11-06 2010-05-14 Ambit Bioscience Corporation Imidazolothiazole compounds as modulators of protein kinase
EP2410987B1 (en) * 2009-03-23 2018-05-16 Ambit Biosciences Corporation Methods of treatment using combination therapy
PL2429524T3 (pl) * 2009-05-14 2020-08-24 Ambit Biosciences Corporation Suszony rozpyłowo preparat AC220

Also Published As

Publication number Publication date
SI2001892T1 (sl) 2013-07-31
EP2001892B1 (en) 2013-04-24
JP4610668B2 (ja) 2011-01-12
US20170348320A1 (en) 2017-12-07
NO342985B1 (no) 2018-09-17
US7820657B2 (en) 2010-10-26
US20140243525A1 (en) 2014-08-28
KR101449057B1 (ko) 2014-10-10
TW200801021A (en) 2008-01-01
CN101448843A (zh) 2009-06-03
CA2646437A1 (en) 2007-09-27
BRPI0708823A2 (pt) 2011-06-14
DK2001892T3 (da) 2013-07-01
RU2441011C2 (ru) 2012-01-27
US8129374B2 (en) 2012-03-06
CN101448843B (zh) 2012-05-09
US8557810B2 (en) 2013-10-15
KR20080108548A (ko) 2008-12-15
AU2007227495B2 (en) 2013-02-21
CA2646437C (en) 2016-05-17
RU2008141169A (ru) 2010-04-27
NZ571566A (en) 2011-07-29
US20120129850A1 (en) 2012-05-24
JP5395017B2 (ja) 2014-01-22
BRPI0708823B1 (pt) 2022-01-18
PT2001892E (pt) 2013-07-04
PL2001892T3 (pl) 2013-09-30
TWI409267B (zh) 2013-09-21
WO2007109120A2 (en) 2007-09-27
US20100298313A1 (en) 2010-11-25
KR101549364B1 (ko) 2015-09-01
IL194076A (en) 2015-05-31
US20070232604A1 (en) 2007-10-04
MY145070A (en) 2011-12-15
EP2001892A2 (en) 2008-12-17
KR20140091619A (ko) 2014-07-21
US20150126505A1 (en) 2015-05-07
WO2007109120A3 (en) 2007-12-27
ES2422890T3 (es) 2013-09-16
NO20084374L (no) 2008-11-05
US8921546B2 (en) 2014-12-30
AU2007227495A1 (en) 2007-09-27
MX2008011684A (es) 2008-12-12
ZA200808178B (en) 2010-11-24
JP2011037858A (ja) 2011-02-24
JP2009530300A (ja) 2009-08-27
IL194076A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
HK1131141A1 (en) Imidazolothiazole compounds for the treatment of disease
IL195571A0 (en) Compounds for the treatment of periodontal disease
GB2454555B (en) Alkoxy compounds for disease treatment
GB0610680D0 (en) Therapeutic compounds
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
GB0603041D0 (en) Therapeutic compounds
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
ZA200808963B (en) Compounds for the treatment of metabolic disorders
EP2035369A4 (en) THERAPEUTIC COMPOUNDS
GB0606663D0 (en) Therapeutic compounds
ZA200805645B (en) Compounds for the treatment of metabolic disorders
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL192851A0 (en) Compounds for the treatment of metabolic disorders
EP2079704A4 (en) THERAPEUTIC COMPOUNDS
IL195392A0 (en) Compounds for the treatment of metabolic disorders
GB0400802D0 (en) Compounds for the treatment of disease
GB0605573D0 (en) Therapeutic Compounds
GB0603455D0 (en) Therapeutic compounds
GB0623740D0 (en) Treatment of disease
GB0608269D0 (en) Therapeutic compounds
IL192982A0 (en) Compounds for the treatment of metabolic disorders
GB0602857D0 (en) The treatment of sialorrhoea
GB0415352D0 (en) Compounds for the treatment of disease
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain
GB0616532D0 (en) Molecular methods for the treatment of disease